1
40
3
-
Hyperlink
A link, or reference, to another resource on the Internet.
URL
https://doi.org/10.20411/pai.v7i2.535
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Update on the Pathogenesis, Virulence, and Treatment of Candida auris
Creator
An entity primarily responsible for making the resource
Richard R Watkins
Rachael Gowen
Michail S Lionakis
Mahmoud Ghannoum
Date
A point or period of time associated with an event in the lifecycle of the resource
2022
Description
An account of the resource
Candida auris is an emerging, multidrug resistant fungal pathogen that causes considerable morbidity and mortality. First identified in Japan in 2009, it has since been reported in more than 40 countries. C. auris can persist for long periods on different environmental surfaces as well as the skin. Clinical isolates are typically resistant to commonly prescribed antifungal drugs. Increasingly recognized as a cause of infections and outbreaks in nosocomial settings, C. auris is difficult to identify using traditional microbiological methods. One of the main reasons for the ongoing spread of C. auris is the multitude of virulence factors it possesses and uses against its human host that enables fungal persistence on the skin surface. Yet, many of the virulence mechanismsare unknown or remain incompletely understood. In this review, we summarize the evolution of virulence of C. auris, offer recommendations for combating this important human pathogen, and suggest directions for further research.
Source
A related resource from which the described resource is derived
Pathog Immun
. 2022 Oct 21;7(2):46-65. doi: 10.20411/pai.v7i2.535. eCollection 2022.
Language
A language of the resource
English
2022
antifungal resistance
Candida auris
Fungemia
immune responses
virulence.
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.2741/1572" target="_blank" rel="noreferrer noopener">http://doi.org/10.2741/1572</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
790-798
Volume
10
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The LEAPS approach to vaccine development
Publisher
An entity responsible for making the resource available
Frontiers in Bioscience
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-01
Subject
The topic of the resource
beta-2-microglobulin; binding-site; Biochemistry & Molecular Biology; Cell Biology; class-ii molecules; dc; dendritic cells; flt3 ligand fl; herpes simplex virus; HIV; human; immune responses; in-vivo; LEAPS constructs; major histocompatibility complex; peptide; protection; review; t-lymphocytes; th1 immune-responses; vaccines
Creator
An entity primarily responsible for making the resource
Zimmerman D H; Rosenthal K S
Description
An account of the resource
The Ligand Epitope Antigen Presentation System ( L. E. A. P. S. TM) approach to vaccine development utilizes immune peptides to promote the immunogenicity and influence the type of immune response generated towards epitopes in peptides which may be too small to elicit an immune response. The covalent attachment of these immune peptides to the antigenic peptide promotes the interaction of the epitope with T cells ( T cell binding ligand (TCBL)) or antigen presenting cells ( immune cell binding ligand (ICBL)) and ultimately promotes binding with the T cell receptor on CD4 or CD8 T cells. The "J" ICBL/TCBL peptide derived from the beta-2-microglobulin chain of MHC I molecules promotes Th1 type responses to the antigenic peptide while the "G" ICBL/TCBL peptide derived from the beta chain of MHC II molecules promotes Th2 types of responses. The efficacy of this approach has been demonstrated by characterization of the immune responses to L. E. A. P. S. vaccines and by elicitation of protection from infectious challenge with herpes simplex virus and other pathogens. The protection studies show that the L. E. A. P. S. approach allows customization of the immune response appropriate for inducing protection from disease. The theory, background, examples and studies of the mechanism of action of the L. E. A. P. S. vaccines will be discussed.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2741/1572" target="_blank" rel="noreferrer noopener">10.2741/1572</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2005
beta-2-microglobulin
binding-site
Biochemistry & Molecular Biology
Cell Biology
class-ii molecules
dc
dendritic cells
flt3 ligand fl
Frontiers in Bioscience
herpes simplex virus
HIV
Human
immune responses
in-vivo
Journal Article
LEAPS constructs
major histocompatibility complex
peptide
protection
review
Rosenthal K S
T-Lymphocytes
th1 immune-responses
Vaccines
Zimmerman D H
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.intimp.2009.12.016" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.intimp.2009.12.016</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
412-421
Issue
4
Volume
10
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model
Publisher
An entity responsible for making the resource available
International Immunopharmacology
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-04
Subject
The topic of the resource
acellular pertussis-vaccine; auto-immune; beta-chain; binding-site; Collagen induced arthritis; identification; immune responses; immunogenicity; Immunology; inflammation; peptide analog; Pharmacology & Pharmacy; Regulation of cytokines in autoimmunity; regulatory t-cells; rheumatoid-arthritis; Therapeutic vaccine; transgenic mice; Vaccines for autoimmunity
Creator
An entity primarily responsible for making the resource
Zimmerman D H; Taylor P; Bendele A; Carambula R; Duzant Y; Lowe V; O'Neill S P; Talor E; Rosenthal K S
Description
An account of the resource
The mouse model of collagen induced arthritis (CIA) effectively mimics human disease and thus is useful for testing and development of rheumatoid arthritis (RA) therapies. We developed a Ligand Epitope Antigen Presentation System (LEAPS) peptide hetero-conjugate vaccine containing an epitope of human collagen type II (CEL-2000) that acted as a therapeutic vaccine in the collagen induced arthritis (CIA) mouse model. LEAPS technology converts a small peptide containing a disease specific epitope into an immunogen by attaching it to an immune or T cell binding peptide (I/TCBL). For CEL-2000, a peptide from human collagen type II (254-273) is attached to the I/TCBL peptide from human in microglobulin (J). Treatment with CEL-2000 limited disease (CIA) progression, as demonstrated by reduced Arthritic Index (AI) score, and footpad swelling. Efficacy was confirmed by histopathological microscopic examination of tissues at the end of the study. CEL-2000 limited disease progression as well or better than the etanercept (Enbrel) therapeutic control with significantly better histopathological results than the etanercept treated mice. Most interestingly, CEL-2000 therapy modulated serum cytokine levels with an increase in IL-12p70 and IL-10, which are not seen with etanercept therapy, and reduced IL-17 and INF-alpha, also seen with etanercept, among other cytokines studied. CEL-2000 was safe and well tolerated for the mice that received 5 injections given every 2 weeks in a 90 day study supporting its potential usage for long term therapy. These studies demonstrate that fewer treatments with CEL-2000 provide therapy at least as effective as etanercept by specifically modulating the disease producing autoimmune response. (C) 2010 Elsevier B.V. All rights reserved.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.intimp.2009.12.016" target="_blank" rel="noreferrer noopener">10.1016/j.intimp.2009.12.016</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2010
acellular pertussis-vaccine
auto-immune
Bendele A
beta-chain
binding-site
Carambula R
Collagen induced arthritis
Duzant Y
identification
immune responses
immunogenicity
Immunology
Inflammation
International Immunopharmacology
Journal Article
Lowe V
O'Neill S P
peptide analog
Pharmacology & Pharmacy
Regulation of cytokines in autoimmunity
regulatory t-cells
rheumatoid-arthritis
Rosenthal K S
Talor E
Taylor P
Therapeutic vaccine
Transgenic mice
Vaccines for autoimmunity
Zimmerman D H